PCM
TERN

Polymer Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

Polymer Capital Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,144
Closed -$76.2K – 985
2025
Q3 		$76.2K Buy
+10,144
New +$64.8K 0.01% 739

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CLGM
Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return

Polymer Capital Management's TERN Position: Q4 2025 in Review

Polymer Capital Management sold out of Terns Pharmaceuticals (TERN) in Q4 2025, closing a stake of 10,144 shares — an estimated $76.2K sold.

Polymer Capital Management first reported a position in TERN in Q3 2025 and held it in 1 quarter. The position peaked at $76.2K in Q3 2025. 248 funds tracked by Wall St. Rank hold TERN as of Q4 2025.

  • Polymer Capital Management reported no remaining Terns Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Polymer Capital Management sold 10,144 Terns Pharmaceuticals shares in Q4 2025, an estimated $76.2K.
  • Polymer Capital Management first reported a position in Terns Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Polymer Capital Management's Terns Pharmaceuticals position peaked at $76.2K in Q3 2025.
  • 248 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q4 2025.

Based on Polymer Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.